FIELD: chemistry.
SUBSTANCE: application of lornooxycam and enol ethers of 6-chloro-4-hydroxy-2-methyl-N-(2-pyridil)-2H-thieno[3,2-e]-1,2-thiazin-3-carboxylic acid amide-1,1-dioxide (including 6-chloro-4-(1-(ethoxycarbamoyloxy)ethoxy)-2-methyl-N-(2-pyridil)-2H-thieno [2,3-e]-1,2-thiazin-3-carboxylic acid amide-1,1-dioxide) is proposed for pharmaceutical composition obtaining used at prevention or treatment of Alzheimer disease ( AD) or arteriosclerosis.
EFFECT: lornooxycam decrease the Aβ-42/Aβ-40 level (efficiency parametre of Alzheimer disease treatment), has low side effects in combination with high treatment efficiency parametre in comparison with other means
3 cl, 7 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY EFFECT | 2020 |
|
RU2752764C1 |
| AMIDINE DERIVATIVE SALTS AND CYCLOOXYGENASE INHIBITOR, METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF | 1996 |
|
RU2167856C2 |
| SUBSTITUTED TETRAHYDRO-, OR HEXAHYDROCYCLOPENT/B/ INDOLES OR THEIR PHARMACEUTICALLY ACCEPTABLE ADDITIVE SALTS AND METHOD FOR THEIR PRODUCTION | 1992 |
|
RU2077530C1 |
| SPECIFIC 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES | 1998 |
|
RU2186762C2 |
| 5-HT RECEPTOR AGONIST COMPOUNDS FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2569056C2 |
| COMBINATION CONTAINING A COMPOUND OF ANGIOTENSIN II-ANTAGONISTIC ACTIVITY | 1997 |
|
RU2188013C2 |
| ANTHRANILIC ACID AND THIOANTHRANILIC ACID N-ARYLAMIDES | 1999 |
|
RU2286338C2 |
| APPLICATION OF (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN DEMENTIA AND PARKINSON'S DISEASE TREATMENT | 2003 |
|
RU2332218C2 |
| MODULATION sAPP, sAPPα AND BDNF LEVELS IN INDIVIDUALS DIAGNOSED WITH FXS AND ASD | 2013 |
|
RU2675252C2 |
| 3-(5)-HETEROARYL-SUBSTITUTED PYRAZOLES AS KINASE P38 INHIBITORS | 1998 |
|
RU2249591C2 |
